CN Patent

CN101918390A — (e)-n-{4-[3-氯-4-(2-吡啶基甲氧基)苯胺基]-3-氰基-7-乙氧基-6-喹啉基}-4-(二甲基氨基)-2-丁烯酰胺的马来酸盐及其结晶形式

Assigned to Wyeth LLC · Expires 2010-12-15 · 15y expired

What this patent protects

本发明涉及(E)-N-{4-[3-氯-4-(2-吡啶基甲氧基)苯胺基]-3-氰基-7-乙氧基-6-喹啉基}-4-(二甲基氨基)-2-丁烯酰胺的马来酸盐形式，制备结晶马来酸盐形式的方法，和有关的化合物，以及包含它们的药物组合物。所述马来酸盐可用于治疗癌、特别是受表皮生长因子受体家族激酶影响的那些癌。

USPTO Abstract

本发明涉及(E)-N-{4-[3-氯-4-(2-吡啶基甲氧基)苯胺基]-3-氰基-7-乙氧基-6-喹啉基}-4-(二甲基氨基)-2-丁烯酰胺的马来酸盐形式，制备结晶马来酸盐形式的方法，和有关的化合物，以及包含它们的药物组合物。所述马来酸盐可用于治疗癌、特别是受表皮生长因子受体家族激酶影响的那些癌。

Drugs covered by this patent

neratinib-maleate (NERATINIB MALEATE)

Patent Metadata

Patent number: CN101918390A
Jurisdiction: CN
Classification: —
Expires: 2010-12-15
Drug substance claim: No
Drug product claim: No
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.